AbbVie records a $3.5 billion impairment charge following the failure of emraclidine in Phase II schizophrenia trials.

US biopharma Biohaven and Dutch biotech Merus have announced a research collaboration and license agreement to co-develop ...

City Therapeutics partners with Bausch + Lomb to develop an RNAi-based therapy for geographic atrophy, leveraging City’s RNAi ...

Teva partners with Klinge Biopharma and Formycon to commercialize FYB203, an Eylea biosimilar, as Ahzantive in Europe and ...

Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...

China’s National Medical Products Administration (NMPA) has approved French Pharma major Sanofi’s Sarclisa (isatuximab), an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) ...

New export figures for November from Statistics Denmark show that medicine constitutes a significant part of total Danish ...

A clinical-stage biopharma company focused on developing therapies for obesity and other cardiometabolic disorders.

Among significant news last week, the US Food and Drug Administration (FDA) required Agios Pharmaceuticals to amend the label ...

Sage Therapeutics’ shares jumped over 45% to $8.09 in after-hours on Friday, after the company confirmed that biotech major ...

South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, ...

The US Food and Drug Administration (FDA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix, GSK’s recombinant zoster vaccine for the prevention of ...